Weibo Wu
Impact in
-
- Pharmacological Effects of Natural Compounds
-
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 5
- SARS-CoV-2 and COVID-19 Research 3
- SARS-CoV-2 detection and testing 2
-
- Long-Term Effects of COVID-19 4
- Co-authors
- Caiming Chen (2 shared papers)Jianfeng Chen (1 shared paper)Yingxia Liu (7 shared papers)Fuxiang Wang (4 shared papers)Mengli Cao (5 shared papers)Chuming Chen (6 shared papers)Yan Chen (1 shared paper)Guanhu Yang (1 shared paper)
- Journals
- Frontiers in Oncology (1 paper)BMJ Open (1 paper)Journal of Pharmaceutical and Biomedical Analysis (1 paper)BMC Infectious Diseases (1 paper)Frontiers in Medicine (1 paper)
- Partner nations
- ChinaUnited StatesNetherlands
In The Last Decade
Weibo Wu
12 papers receiving 208 citations
Peers
Comparison fields: 5 of 80
- Pharmacology 24
- Infectious Diseases 50
- Health Informatics 3
- Molecular Medicine 10
- Rheumatology 27
Countries citing papers authored by Weibo Wu
This map shows the geographic impact of Weibo Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weibo Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weibo Wu more than expected).
Fields of papers citing papers by Weibo Wu
This network shows the impact of papers produced by Weibo Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weibo Wu. The network helps show where Weibo Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Weibo Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 84 | |
| 2 | 2020 | 32 | |
| 3 | 2020 | 22 | |
| 4 | 2020 | 22 | |
| 5 | 2020 | 12 | |
| 6 | 2023 | 12 | |
| 7 | 2018 | 12 | |
| 8 | 2020 | 6 | |
| 9 | 2023 | 4 | |
| 10 | 2021 | 3 | |
| 11 | 2024 | 1 | |
| 12 | 2022 | 1 | |
| 13 | 2023 | 0 | |
| 14 | 2025 | 0 | |
| 15 | 2022 | 0 |
About Weibo Wu
Weibo Wu is a scholar working on Infectious Diseases, Neurology, Molecular Biology, Oncology and Epidemiology, having authored 15 papers that have together received 211 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (5 papers), Long-Term Effects of COVID-19 (4 papers), SARS-CoV-2 and COVID-19 Research (3 papers), SARS-CoV-2 detection and testing (2 papers), Inflammasome and immune disorders (2 papers), COVID-19 diagnosis using AI (1 paper), Poxvirus research and outbreaks (1 paper) and Natural product bioactivities and synthesis (1 paper). The work is most often cited by research in Pharmacology (24 citations), Infectious Diseases (50 citations), Health Informatics (3 citations), Molecular Medicine (10 citations) and Rheumatology (27 citations). Weibo Wu has collaborated with scholars based in China, United States and Netherlands. Frequent co-authors include Caiming Chen, Jianfeng Chen, Yingxia Liu, Fuxiang Wang, Mengli Cao, Chuming Chen, Jianfeng Chen, Yan Chen, Guanhu Yang and Songhe Jiang. Their work appears in journals such as Frontiers in Oncology, BMJ Open, Journal of Pharmaceutical and Biomedical Analysis, BMC Infectious Diseases and Frontiers in Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.